News | May 03, 2024
Moderna posts Q1 2024 revenues at US$167 million
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
2024 full-year revenue guidance raised by US$ 2 billion
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
New solvent-free micronization technology expanded at the Darmstadt site in Germany
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
